2017 Section 7 Green Book

K UMAR ET AL .

3. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in sur- vival rate between smokers and nonsmokers with HPV 16-associated ton- sillar carcinomas. Int J Cancer 2008;122:2656–2664. 4. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007;110:1429–1435. 5. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 2002;94: 2967–2980. 6. Parsons JT, Mendenhall WM, Million RR, Stringer SP, Cassisi NJ. The management of primary cancers of the oropharynx: combined treatment or irradiation alone? Semin Radiat Oncol 1992;2:142–148. 7. [No authors listed]. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685–1690. 8. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and sur- vival after neoadjuvant organ-preserving chemotherapy for advanced laryn- geal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994;12:1592–1599. 9. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081–2086. 10. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69–76. 11. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582–3589. 12. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 2008;113:497–507. 13. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008;26:3138–3146. 14. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142–4148. 15. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35. 16. May JT, Rao N, Sabater RD, et al. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck 2013;35:1796–1800. 17. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papilloma- virus in oropharynx cancer in TAX 324: a subset analysis from an interna- tional phase III trial. Ann Oncol 2011;22:1071–1077. 18. Garden AS, Harris J, Trotti A, et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008;71:1351–1355. 19. Setton J, Caria N, Romanyshyn J, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan–Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2012;82:291–298. 20. Prestwich RJ, Kancherla K, Oksuz DC, et al. A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer. Radiat Oncol 2010;5:121. 21. Greven KM, White DR, Browne JD, Williams DW III, McGuirt WF Sr, D’Agostino RB Jr. Swallowing dysfunction is a common sequelae after che- moradiation for oropharynx carcinoma. Am J Clin Oncol 2008;31:209–212.

22. Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer treatment: patients’ perspectives. Otolaryngol Head Neck Surg 2011;145:767–771. 23. Best SR, Ha PK, Blanco RG, et al. Factors associated with pharyngoeso- phageal stricture in patients treated with concurrent chemotherapy and radi- ation therapy for oropharyngeal squamous cell carcinoma. Head Neck 2011;33:1727–1734. 24. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiother- apy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010;28:2732–2738. 25. Setton J, Lee NY, Riaz N, et al. A multi-institution pooled analysis of gas- trostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. Cancer 2015;121:294– 301. 26. Shiley SG, Hargunani CA, Skoner JM, Holland JM, Wax MK. Swallowing function after chemoradiation for advanced stage oropharyngeal cancer. Otolaryngol Head Neck Surg 2006;134:455–459. 27. Haughey BH, Sinha P. Prognostic factors and survival unique to surgically treated p16 1 oropharyngeal cancer. Laryngoscope 2012;122 Suppl 2:S13– S33. 28. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630–5636. 29. Moore EJ, Henstrom DK, Olsen KD, Kasperbauer JL, McGree ME. Trans- oral resection of tonsillar squamous cell carcinoma. Laryngoscope 2009; 119:508–515. 30. Hurtuk A, Agrawal A, Old M, Teknos TN, Ozer E. Outcomes of transoral robotic surgery: a preliminary clinical experience. Otolaryngol Head Neck Surg 2011;145:248–253. 31. Hurtuk AM, Marcinow A, Agrawal A, Old M, Teknos TN, Ozer E. Qual- ity-of-life outcomes in transoral robotic surgery. Otolaryngol Head Neck Surg 2012;146:68–73. 32. Weinstein GS, O’Malley BW Jr, Magnuson JS, et al. Transoral robotic sur- gery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope 2012;122:1701–1707. 33. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers version 2.2014. Available at: http://www.nccn.org/professionals/physician_ gls/f_guidelines.asp. Accessed May 1, 2015. 34. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–1952. 35. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:401–408. 36. Padilla GV, Grant MM. Psychosocial aspects of artificial feeding. Cancer 1985;55(1 Suppl):301–304. 37. Roberge C, Tran M, Massoud C, et al. Quality of life and home enteral tube feeding: a French prospective study in patients with head and neck or oesophageal cancer. Br J Cancer 2000;82:263–269. 38. Radhakrishnan R, Solomon M, Satyamoorthy K, Martin LE, Lingen MW. Tissue microarray – a high-throughput molecular analysis in head and neck cancer. J Oral Pathol Med 2008;37:166–176. 39. The R project for statistical computing. R: a language and environment for statistical computing. Available at: http://www.R-project.org/. Accessed May 1, 2015. 40. Therneau T, Atkinson B, Ripley B. Rpart: recursive partitioning and regres- sion trees. R package version 4.1-8. Available at: https://cran.r-project.org/ web/packages/rpart/rpart.pdf. Accessed May 1, 2015. 41. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radio- therapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–1944.

HEAD & NECK—DOI 10.1002/HED APRIL 2016

167